But as anyone who has been paying attention well knows, Trump did try to help by promoting the use of hydroxychloroquine (HCQ), which the U.S. Food and Drug Administration (FDA) has continued to stonewall at the expense of the tens of thousands of lives that have now been needlessly lost.
At last count, upwards of 48,000 Americans have died just since July 1 when the FDA delayed issuing an Emergency Use Authorization (EUA) for HCQ. Doctors and medical professionals all across the country have repeatedly tried to get the FDA to cooperate with their requests to administer HCQ to their patients, only to have the FDA reject their petitions.
The latest rejection came on Aug. 10 when the FDA told Dr. John McKinnon and his team from Henry Ford Hospital in Detroit that they cannot prescribe HCQ either for outpatient prevention or for inpatient early treatment. Under no circumstances is HCQ allowed to be prescribed, in other words, even though a clinical trial conducted by Dr. McKinnon resulted in a 51 percent reduction in deaths when HCQ treatment was initiated within 24 hours of a patient being admitted to the hospital.
Dr. Peter McCullough and his cardiology team at the Baylor Heart and Vascular Institute in Dallas apparently peer-reviewed Dr. McKinnon's paper and findings, agreeing that HCQ is a useful tool in the fight against the Wuhan coronavirus (COVID-19). But this is not so, according to the FDA, which continues to resist all attempts by actual doctors to provide much-needed relief to their suffering patients.